Symbiotec Pharmalab

Incorporated in 2002, Symbiotec Pharmalab is an integrated pharmaceutical manufacturing company with roots in steroidal hormone API manufacturing. The company develops and manufactures APIs, nutritional ingredients and specialty products for pharmaceutical, nutraceutical and wellness applications. As of June 30, 2025, Symbiotec operated two industrial-scale API manufacturing facilities with chemical synthesis capacity of 584.67 MT and fermentation capacity of 300 KL. The company has regulatory approvals and certifications from the US FDA, EU-GMP, South Korea and other international regulatory authorities. Its competitive strengths include expertise in corticosteroid and steroidal hormone APIs, long-standing customer relationships, backward-integrated manufacturing capabilities, research and development capabilities and a global regulatory track record. The company is promoted by Anil Satwani, Kashish Satwani, Sushil Satwani and Satwani Holdings LLP.

Symbiotec Pharmalab IPO is a book-built mainboard issue of ₹1,757 crore comprising a fresh issue of ₹150 crore and an offer for sale of ₹1,607 crore. The IPO price band is ₹938 to ₹988 per share and the minimum lot size is 15 shares, requiring a minimum retail investment of ₹14,820 at the upper price band. The fresh issue proceeds are proposed to be used primarily for prepayment or repayment of certain outstanding borrowings, with the balance intended for general corporate purposes, while the OFS proceeds will go to the selling shareholders. At the upper price band, the company is valued at approximately ₹6,244.43 crore, implying a post-issue P/E of about 56.81 times based on FY2026 EPS of ₹17.39. Key strengths include its specialised API portfolio, regulatory approvals, integrated manufacturing platform and established customer relationships, while key risks include dependence on pharmaceutical markets, regulatory compliance, customer concentration and the relatively high IPO valuation. The issue is expected to list on BSE and NSE, with JM Financial, Avendus Capital, Motilal Oswal Investment Advisors and Nomura Financial Advisory & Securities acting as book-running lead managers.